Scott Requadt - 26 Jul 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)

Role: Chief Executive Officer, Director
Signature: /s/ Mary Kay Fenton, attorney-in-fact
Issuer symbol: TRML
Transactions as of: 26 Jul 2022
Net transactions value: +$36,571
Form type: 4
Filing time: 28 Jul 2022, 19:52:49 UTC
Previous filing: 26 Jul 2022
Next filing: 02 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TALS	Common Stock	Purchase	$23,439	+5,528	+1.2%	$4.24	466,208	26 Jul 2022	Direct	F1
transaction	TALS	Common Stock	Purchase	$13,132	+3,090	+0.66%	$4.25	469,298	28 Jul 2022	Direct
holding	TALS	Common Stock						449,766	26 Jul 2022	See Footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.18 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	These shares are held by Requadt Family Limited Partnership. The Reporting Person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.18 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

These shares are held by Requadt Family Limited Partnership. The Reporting Person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership.